Nov 27, 2001
Guidant Holds Conference Call to Review MADIT II Study

Live Webcast Available

Indianapolis, Ind. - Guidant Corporation (NYSE and PCX: GDT), a world leader in the treatment of cardiovascular and vascular disease, announced today that it will conduct a conference call to review the Multi-center Automatic Defibrillator Implantation Trial (MADIT II). The call, which will be webcast live, will take place on Tuesday, Nov. 27, at 1 p.m. (EST).

Participating on the call will be Fred McCoy, president, Cardiac Rhythm Management, and the study's principal investigator Arthur J. Moss, M.D., University of Rochester Medical Center, Rochester, N.Y.

As announced last week, the study's independent data and safety monitoring board terminated the study early due to a 30 percent mortality reduction in those heart attack survivors receiving an implantable defibrillator compared to those receiving conventional treatment.

The live webcast of the call will be accessible through Guidant's website or at CCBN's individual investor center at CompanyBoardroom.com. The webcast will be archived on both sites for future on-demand replay.

Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to 7 million cardiac and vascular patients worldwide. The company, driven by a strong entrepreneurial culture of 10,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions.

System requirements for the webcast include Internet Explorer 5.0 (or higher) or Netscape Navigator 4.0 (or higher). Users also should have the most recent version of Windows Media Player, which can be downloaded for free. Users may experience varying levels of performance based on their connection speed, system capabilities and presence of a corporate firewall. To ensure a connection, users should go to the program five to 15 minutes before its start.